The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Toth, Peter P ^a,b   Simko, Robert J ^c   Palli, Swetha R ^d   Koselleck, Dawn ^c   Quimbo, Ralph A ^d   Cziraky, Mark J ^d  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c ABBOTT LABORATORIES   (United States)

^d HEALTHCORE INC   (United States)

Author keywords

ADA treatment goals; Diabetes; Lipid subfractions; Microvascular complications; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CHOLESTEROL ESTER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMORBIDITY; DEPRESSION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL NEUROPATHY; RISK ASSESSMENT;

ADULT; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84866153526     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-109     Document Type: Article

References (31)

1. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126.
2. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010, 6:19-25. 10.1038/nrendo.2009.213, 19859073.
3. Misra A, Kumar S, Kishore VN, Kumar A. The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs 2003, 3:325-338. 10.2165/00129784-200303050-00004, 14728067.
4. National Diabetes Statistics 2011, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf..
5. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006, 124:1754-1760. 10.1001/archopht.124.12.1754, 17159036.
6. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004, 18:18-26. 10.1016/S1056-8727(03)00035-7, 15019595.
7. Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Pract 2005, 68(Suppl 2):S3-14.
8. Harris SB, Naqshbandi M, Bhattacharyya O, et al. Major gaps in diabetes clinical care among Canada's First Nations: results of the CIRCLE study. Diab Res Clin Pract 2011, 92:272-279.
9. Larsson LI, Alm A, Lithner F, Dahlen G, Bergstrom R. The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umea. Acta Ophthalmol Scand 1999, 77:585-591. 10.1034/j.1600-0420.1999.770522.x, 10551307.
10. Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy?. Am J Kidney Dis 1993, 22:196-201.
11. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997, 46:665-670. 10.2337/diabetes.46.4.665, 9075809.
12. Standards of medical care in diabetes--2010. Diabetes Care 2010, 33(Suppl 1):S11-S61. 2797382, 20042772.
13. National Cholesterol Education Program Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication No. 02-5215 2002, MD: National Heart Lung and Blood Institute, Bethesda, National Cholesterol Education Program.
14. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007, 115:1481-1501. 10.1161/CIRCULATIONAHA.107.181546, 17309915.
15. Leslie RS. Using arrays to calculate medication utilization 2007, SAS Global Forum.
16. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12. 10.1111/j.1524-4733.2006.00139.x, 17261111.
17. Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Br Med J 2006, 332:1115-1124.
18. Kordonouri O, Danne T, Hopfenmuller W, Enders I, Hovener G, Weber B. Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus?. Acta Paediatr 1996, 85:43-48. 10.1111/j.1651-2227.1996.tb13888.x, 8834978.
19. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998, 21:160-178. 10.2337/diacare.21.1.160, 9538988.
20. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003, 26(Suppl 1):S83-S86.
21. Zoppini G, Negri C, Stoico V, et al. Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism 2012, 61:22-29. 10.1016/j.metabol.2011.05.004, 21676418.
22. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetology 2012, 11:29.
23. Grundy SM, Vega GL, Tomassini JE, Tershakovec AM. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol 2009, 104:548-553. 10.1016/j.amjcard.2009.04.018, 19660610.
24. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23. 10.2337/diacare.26.1.16, 12502653.
25. Querton L, Buysschaert M, Hermans MP. Hypertriglyceridemia and residual dyslipidemia in statin-treatment patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol
26. Hermans MP, Ahn SA, Rousseau MF. log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes mellitus. Cardiovasc Diabetology 2010, 9:88.
27. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
28. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697. 10.1016/S0140-6736(07)61607-9, 17988728.
29. Toth PP. Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. Int J Clin Pract 2009, 63:903-911. 10.1111/j.1742-1241.2009.02053.x, 19490201.
30. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
31. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485-493. 10.1053/j.ajkd.2004.11.004, 15754270.